Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Vor Biopharma ( (VOR) ) has provided an update.
On June 25, 2025, Vor Biopharma entered into an exclusive license agreement with RemeGen Co., Ltd., granting Vor Biopharma rights to develop and commercialize the fusion protein product, telitacicept, outside of Greater China. The agreement involves an upfront payment of $125 million and potential milestone payments exceeding $4 billion. Additionally, Vor Biopharma announced a private placement to raise $175 million for advancing its clinical pipeline. Concurrently, Dr. Robert Ang resigned as CEO, with Jean-Paul Kress appointed as the new CEO and Chairman, bringing extensive leadership experience to guide the company’s growth in autoimmune disease treatment.
The most recent analyst rating on (VOR) stock is a Hold with a $0.40 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
Spark’s Take on VOR Stock
According to Spark, TipRanks’ AI Analyst, VOR is a Underperform.
Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.
To see Spark’s full report on VOR stock, click here.
More about Vor Biopharma
Vor Biopharma is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases. The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide.
Average Trading Volume: 6,833,564
Technical Sentiment Signal: Sell
Current Market Cap: $69.28M
See more data about VOR stock on TipRanks’ Stock Analysis page.